{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:48:29Z","timestamp":1793760509419,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"RheumaDatenRhePort GbR","award":["RheumaDatenRhePort GbR"],"award-info":[{"award-number":["RheumaDatenRhePort GbR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05859-7","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T01:17:29Z","timestamp":1744679849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis \u2013 a retrospective analysis from the RHADAR database"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4105-6064","authenticated-orcid":false,"given":"Linus Maximilian","family":"Risser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-0267","authenticated-orcid":false,"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-7183","authenticated-orcid":false,"given":"Matthias","family":"Englbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-7074","authenticated-orcid":false,"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-3903","authenticated-orcid":false,"given":"Matthias","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-2299","authenticated-orcid":false,"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-4459","authenticated-orcid":false,"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-4497","authenticated-orcid":false,"given":"Peter","family":"Bartz-Bazzanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-7174","authenticated-orcid":false,"given":"Cay","family":"von der Decken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-7326","authenticated-orcid":false,"given":"Kirsten","family":"Karberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-8369","authenticated-orcid":false,"given":"Georg","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8124-2111","authenticated-orcid":false,"given":"Susanna","family":"Sp\u00e4thling-Mestekemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-1717","authenticated-orcid":false,"given":"Christoph","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-5560","authenticated-orcid":false,"given":"Wolfgang","family":"Vorbr\u00fcggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-3085","authenticated-orcid":false,"given":"Martin","family":"Welcker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-7547","authenticated-orcid":false,"given":"Stefan","family":"Kleinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"10","key":"5859_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7326\/0003-4819-131-10-199911160-00009","volume":"131","author":"T Pincus","year":"1999","unstructured":"Pincus T, O\u2019Dell JR, Kremer JM (1999) Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 131(10):768\u2013774. https:\/\/doi.org\/10.7326\/0003-4819-131-10-199911160-00009","journal-title":"Ann Intern Med"},{"issue":"6","key":"5859_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5859_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"issue":"1","key":"5859_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"S Josef","year":"2023","unstructured":"Josef S, Smolen, Robert BM, Landew\u00e9 SA, Bergstra et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"5859_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R (2020) JAK inhibitors in rheumatoid arthritis: an Evidence-Based review on the emerging clinical data. J Inflamm Res 13:519\u2013531. https:\/\/doi.org\/10.2147\/JIR.S219586","journal-title":"J Inflamm Res"},{"issue":"16","key":"5859_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL et al (2020) Trial of Upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383(16):1511\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa2008250","journal-title":"N Engl J Med"},{"issue":"7","key":"5859_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"issue":"2","key":"5859_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","volume":"57","author":"G Kilcher","year":"2018","unstructured":"Kilcher G, Hummel N, Didden EM et al (2018) Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology (Oxford) 57(2):354\u2013369. https:\/\/doi.org\/10.1093\/rheumatology\/kex394","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"5859_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14712598.2024.2358165","volume":"24","author":"TC Mok","year":"2024","unstructured":"Mok TC, Mok CC (2024) Non-TNF biologics and their biosimilars in rheumatoid arthritis. Expert Opin Biol Ther 24(7):599\u2013613. https:\/\/doi.org\/10.1080\/14712598.2024.2358165","journal-title":"Expert Opin Biol Ther"},{"key":"5859_CR10","doi-asserted-by":"publisher","first-page":"764518","DOI":"10.1155\/2013\/764518","volume":"2013","author":"A Arora","year":"2013","unstructured":"Arora A, Mahajan A, Spurden D et al (2013) Long-Term drug survival of TNF inhibitor therapy in RA patients: A systematic review of European National drug registers. Int J Rheumatol 2013:764518. https:\/\/doi.org\/10.1155\/2013\/764518","journal-title":"Int J Rheumatol"},{"issue":"3","key":"5859_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00296-018-4194-y","volume":"39","author":"L Jacob","year":"2019","unstructured":"Jacob L, Chevalier T, Kostev K (2019) Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatol Int 39(3):525\u2013531. https:\/\/doi.org\/10.1007\/s00296-018-4194-y","journal-title":"Rheumatol Int"},{"issue":"11","key":"5859_CR12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s10067-016-3349-z","volume":"35","author":"F Iannone","year":"2016","unstructured":"Iannone F, Sinigaglia L, Favalli EG et al (2016) Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clin Rheumatol 35(11):2649\u20132656. https:\/\/doi.org\/10.1007\/s10067-016-3349-z","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5859_CR13","doi-asserted-by":"publisher","first-page":"e28164","DOI":"10.2196\/28164","volume":"23","author":"S Kleinert","year":"2021","unstructured":"Kleinert S, Bartz-Bazzanella P, von der Decken C et al (2021) A Real-World rheumatology registry and research consortium: the German rheumadatenrheport (RHADAR) registry. J Med Internet Res 23(5):e28164. https:\/\/doi.org\/10.2196\/28164","journal-title":"J Med Internet Res"},{"issue":"10","key":"5859_CR14","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00296-024-05671-9","volume":"44","author":"P Strunz","year":"2024","unstructured":"Strunz P, Englbrecht M, Risser LM et al (2024) Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network. Rheumatol Int 44(10):2057\u20132066. https:\/\/doi.org\/10.1007\/s00296-024-05671-9","journal-title":"Rheumatol Int"},{"key":"5859_CR15","doi-asserted-by":"publisher","first-page":"1395968","DOI":"10.3389\/fimmu.2024.1395968","volume":"15","author":"P Strunz","year":"2024","unstructured":"Strunz P, Englbrecht M, Risser LM et al (2024) Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database. Front Immunol 15:1395968. https:\/\/doi.org\/10.3389\/fimmu.2024.1395968","journal-title":"Front Immunol"},{"key":"5859_CR16","unstructured":"R Core Team (2018) A Language and Environment for Statistical Computing 4.0.4"},{"key":"5859_CR17","unstructured":"RStudio T (2018) RStudio: Integrated Development for R 1.4.1103"},{"issue":"6","key":"5859_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00393-021-01056-6","volume":"80","author":"C Specker","year":"2021","unstructured":"Specker C, Aries P, Braun J et al (2021) Aktualisierte handlungsempfehlungen der Deutschen gesellschaft f\u00fcr rheumatologie f\u00fcr die betreuung von patienten Mit entz\u00fcndlich-rheumatischen erkrankungen Im Rahmen der SARS-CoV-2\/COVID-19-Pandemie einschlie\u00dflich empfehlungen Zur COVID-19-Impfung. Z Rheumatol 80(6):570\u2013587. https:\/\/doi.org\/10.1007\/s00393-021-01056-6","journal-title":"Z Rheumatol"},{"issue":"9","key":"5859_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM et al (2021) Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 80(9):1137\u20131146. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220418","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5859_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219498","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5859_CR21","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","volume":"4","author":"KM Andersen","year":"2022","unstructured":"Andersen KM, Bates BA, Rashidi ES et al (2022) Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID cohort collaborative. Lancet Rheumatol 4(1):e33\u2013e41. https:\/\/doi.org\/10.1016\/S2665-9913(21)00325-8","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"5859_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and Life-Tables. J Roy Stat Soc: Ser B (Methodol) 34(2):187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"issue":"10","key":"5859_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/acr2.11602","volume":"5","author":"S Jeong","year":"2023","unstructured":"Jeong S, George MD, Mikuls TR et al (2023) Changes in patterns of use of advanced therapies following emerging data about adverse events in patients with rheumatoid arthritis from the veterans affairs health system. ACR Open Rheumatol 5(10):563\u2013567. https:\/\/doi.org\/10.1002\/acr2.11602","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"5859_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/acr.22327","volume":"66","author":"A Richter","year":"2014","unstructured":"Richter A, Strangfeld A, Herzer P et al (2014) Sustainability of rituximab therapy in different treatment strategies: results of a 3-Year followup of a German biologics register. Arthritis Care Res (Hoboken) 66(11):1627\u20131633. https:\/\/doi.org\/10.1002\/acr.22327","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"5859_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","volume":"57","author":"AGS Oldroyd","year":"2018","unstructured":"Oldroyd AGS, Symmons DPM, Sergeant JC et al (2018) Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford) 57(6):1089\u20131096. https:\/\/doi.org\/10.1093\/rheumatology\/key036","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5859_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, G\u00f3mez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55(3):523\u2013534. https:\/\/doi.org\/10.1093\/rheumatology\/kev374","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5859_CR27","doi-asserted-by":"publisher","first-page":"A540","DOI":"10.1016\/j.jval.2017.08.803","volume":"20","author":"J Radtchenko","year":"2017","unstructured":"Radtchenko J, Smith Y, Feinberg B (2017) PMS80 - Real-World treatment patterns and time to discontinuation in rheumatoid arthritis patients in the US. Value Health 20(9):A540. https:\/\/doi.org\/10.1016\/j.jval.2017.08.803","journal-title":"Value Health"},{"issue":"11","key":"5859_CR28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00296-021-04989-y","volume":"41","author":"ME Naffaa","year":"2021","unstructured":"Naffaa ME, Hassan F, Golan-Cohen A et al (2021) Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study. Rheumatol Int 41(11):1905\u20131913. https:\/\/doi.org\/10.1007\/s00296-021-04989-y","journal-title":"Rheumatol Int"},{"issue":"12","key":"5859_CR29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/acr2.11629","volume":"5","author":"S Aboulenain","year":"2023","unstructured":"Aboulenain S, Li X, Movahedi M et al (2023) Cardiovascular risk factors and the risk of discontinuation of advanced therapies due to treatment failure in rheumatoid arthritis: results from the Ontario best practices research initiative. ACR Open Rheumatol 5(12):712\u2013717. https:\/\/doi.org\/10.1002\/acr2.11629","journal-title":"ACR Open Rheumatol"},{"key":"5859_CR30","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2147\/PPA.S117774","volume":"10","author":"R Alten","year":"2016","unstructured":"Alten R, Kr\u00fcger K, Rellecke J et al (2016) Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 10:2217\u20132228. https:\/\/doi.org\/10.2147\/PPA.S117774","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"5859_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13075-020-02391-w","volume":"22","author":"KS Bywall","year":"2020","unstructured":"Bywall KS, Kihlbom U, Hansson M et al (2020) Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients. Arthritis Res Ther 22(1):288\u2013w. https:\/\/doi.org\/10.1186\/s13075-020-02391-w","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5859_CR32","doi-asserted-by":"publisher","first-page":"rkac071","DOI":"10.1093\/rap\/rkac071","volume":"6","author":"H Direskeneli","year":"2022","unstructured":"Direskeneli H, Karadag O, Ates A et al (2022) Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study. Rheumatol Adv Pract 6(3):rkac071. https:\/\/doi.org\/10.1093\/rap\/rkac071","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"5859_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","volume":"12","author":"R Kanda","year":"2025","unstructured":"Kanda R, Miyazaki Y, Nakayamada S et al (2025) Effective Second-Line B\/tsDMARDs for patients with rheumatoid arthritis unresponsive to First-Line B\/tsDMARDs from the FIRST registry. Rheumatol Ther 12(2):353\u2013369. https:\/\/doi.org\/10.1007\/s40744-025-00747-9","journal-title":"Rheumatol Ther"},{"key":"5859_CR34","doi-asserted-by":"publisher","unstructured":"Finckh A, Tellenbach C, Herzog L et al (2020) Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and Tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 6(1). https:\/\/doi.org\/10.1136\/rmdopen-2020-001174","DOI":"10.1136\/rmdopen-2020-001174"},{"key":"5859_CR35","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D et al (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"5859_CR36","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","volume":"10","author":"R Alten","year":"2023","unstructured":"Alten R, Burmester GR, Matucci-Cerinic M et al (2023) Comparative effectiveness, time to discontinuation, and Patient-Reported outcomes with baricitinib in rheumatoid arthritis: 2-Year data from the multinational, prospective observational RA-BE-REAL study in European patients. Rheumatol Ther 10(6):1575\u20131595. https:\/\/doi.org\/10.1007\/s40744-023-00597-3","journal-title":"Rheumatol Ther"},{"key":"5859_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/annrheumdis-2020-eular.1243","volume":"79","author":"B Gilbert","year":"2020","unstructured":"Gilbert B, Lauper K, Courvoisier D et al (2020) THU0203\u2005Real world effectiveness of baricitinib in the Swiss rheumatoid arthritis register (SCQM-RA). Ann Rheum Dis 79:325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.1243","journal-title":"Ann Rheum Dis"},{"key":"5859_CR38","unstructured":"EMA Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9\u201312 January 2023. Available via. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023. Accessed 22.02 2024"},{"key":"5859_CR39","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Cruz B, Otero-Varela L, Freire-Gonz\u00e1lez M et al (2024) Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. Ann Rheum Dis ard\u2013225271. https:\/\/doi.org\/10.1136\/ard-2023-225271","DOI":"10.1136\/ard-2023-225271"},{"issue":"10","key":"5859_CR40","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D et al (2022) Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration. Ann Rheum Dis 81(10):1358\u20131366. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222586","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5859_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00393-023-01323-8","volume":"82","author":"C Fiehn","year":"2023","unstructured":"Fiehn C, Zinke S, Haas JS et al (2023) Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis. Z Rheumatol 82(9):739\u2013753. https:\/\/doi.org\/10.1007\/s00393-023-01323-8","journal-title":"Z Rheumatol"},{"issue":"10","key":"5859_CR42","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","volume":"61","author":"A Barbulescu","year":"2022","unstructured":"Barbulescu A, Askling J, Chatzidionysiou K et al (2022) Effectiveness of baricitinib and Tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford) 61(10):3952\u20133962. https:\/\/doi.org\/10.1093\/rheumatology\/keac068","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5859_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K et al (2024) Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis 83(2):139\u2013160. https:\/\/doi.org\/10.1136\/ard-2023-223850","journal-title":"Ann Rheum Dis"},{"key":"5859_CR44","doi-asserted-by":"publisher","first-page":"152314","DOI":"10.1016\/j.semarthrit.2023.152314","volume":"64","author":"L Scheepers","year":"2024","unstructured":"Scheepers L, Yang Y, Chen YL et al (2024) Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Semin Arthritis Rheum 64:152314. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152314","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5859_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA et al (2024) Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study). Ann Rheum Dis 83(4):421\u2013428. https:\/\/doi.org\/10.1136\/ard-2023-224670","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05859-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:45:17Z","timestamp":1747986317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05859-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["5859"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05859-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. A draft of the study was submitted to the Ethics Committee of the Hannover Medical School (Application 11291_BO_K_2024, date March 1, 2024). The Ethics Committee advised that the retrospective analysis of anonymized clinical data does not require ethical approval according to German law. All participants provided written consent for inclusion in the RHADAR database and for analysis of their pseudonymised data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No part of this manuscript, including text and graphics, has been copied, submitted or previously published, either in whole or in part or in any language, except for partial data publication in congress abstracts (see below). The authors declare that no artificial intelligence (AI) tools were used during the writing and editing process of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"LR declares that he has received travel and meeting support from Abbvie, Boehringer, Biocon Biologics Germany GmbH and speaking fees from Novartis. TW received honoraria for lectures from Abbvie, Amgen, BMS, Celgene, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, UCB. ME received payment for data analysis from RHADAR and consulting fees from Abbvie and RHADAR as well as speaker fees and honoraria for lectures from Sanofi, Swedish orphan Biovitrum and Abbvie. ME leadership or fiduciary role from Chugai. P-PS received speaker\u2019s fees and travel grants from Janssen-Cilag Galapagos, Eli Lilly, Boehringer\/Ingelheim and AbbVie less than $10,000 each as well as research funding from Chugai 25000$. MF received speaker\u2019s fees, travel grants or compensation for board memberships from AbbVie, Amgen, AstraZeneca, Novartis, Janssen, Hexal, Pfizer, Takeda, UCB and Eli Lilly. MS received speaker\u2019s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer\/Ingelheim, Celgene, Chugai\/Roche, Eli Lilly, Genzyme, Gilead, Hexal\/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda Shire, UCB less than $ 10,000 each. MG received travel grants, compensation for advisory boards or speaker\u2019s fees from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda. PBB declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. CvdD received travel grants from Galapagos and Abbvie. KK received speaker fees from Abbvie and UCB. GG received speaker fees and travel grants from Abbvie, Janssen, Galapagos, and Lilly. SS-M received speaker fees from Abbvie, Astra Zeneca, Boerhringer-Ingelheim, BMS, Galapagos, GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, UCB. CK declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. WV declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. MW declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SK received grants from Abbvie, Novartis, and sparrow for phase 2\/3 clinical trials and cosulting or speaker fees from Abbvie, Celgene, Chugai, Galapagos, Novartis, and Siemens Healthineers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}